Zeo Energy ($ZEO): Long-Time Solar Customers Saving About 50% Versus Utility Rates as Electricity Prices Climb
Zeo Energy (Nasdaq: ZEO) says customers who installed solar systems three or more years ago are now saving about 50% on their solar power compared with buying the same electricity from their utilities. Rising utility prices are widening that gap. Federal data show residential electricity rates in Zeo’s five core markets rose 28% to 40% from 2021 to 2025, faster than the national average, with Pennsylvania up the most at 40%. The U.S. Energy Information Administration expects prices to keep climbing through 2027. Solar payments are typically set in advance, so customers’ savings grow as utility rates rise. Zeo has built a residential solar business generating more than $70 million in annual revenue, and it sees the widening cost advantage as an opportunity to expand its reach.
Full press release: redchip.news/4tedSsD
Gorilla Technology ($GRRR): Q3 Revenue Surges 163% to a Record $69.5 Million, Exceeding Guidance by 39%
Gorilla Technology (Nasdaq: GRRR) reported record third-quarter revenue of $69.5 million, up 163% from a year ago and 39% from Q2. That beat the top of its guidance by 39%, driven by higher deliveries of AI infrastructure. Profitability also turned around. Gross profit swung to $8.9 million from a $2.1 million loss in Q2, and gross margin recovered 17 percentage points to 12.8%. During the quarter, Gorilla invested about $218 million in AI compute and data center infrastructure, largely to deliver its Yotta 1 contract. The company reaffirmed its 2026 revenue outlook of at least $200 million and its 2027 target of $450 million to $500 million.
Full press release: redchip.news/4960yxf
6
831
Foremost Clean Energy ($FMST): Uranium and Capital Markets Veteran Rob Chang Named President and CEO
Foremost Clean Energy (Nasdaq: FMST) has appointed Rob Chang as President and CEO, bringing nearly 30 years of experience in mining, capital markets and public-company leadership. Chang spent nearly a decade as Head of Metals & Mining Research at Cantor Fitzgerald, where he covered uranium. He also co-founded Gryphon Digital Mining and took it from inception to a Nasdaq listing. He also sits on the board of uranium producer Ur-Energy. Chang takes over as Foremost follows up on recent uranium discoveries at Hatchet Lake and Turkey Lake, backed by Denison Mines (NYSE-A: DNN), its largest shareholder. Interim CEO David Cates, who also leads DNN, will remain on the board.
Full press release: redchip.news/3XD10R1
1
148
Join Our LIVE Investor Webinar Q&A With FibroBiologics - LIVE NOW teapawt.net/i/broadcasts/2ybQRrlRO…
156
⏳ Starting in 30 Minutes: FibroBiologics (NASDAQ: FBLG) Live Investor Webinar at 4:15 PM ET
Last chance to register. In 30 minutes, FibroBiologics management goes live to discuss how the company is turning the body’s most common connective tissue cell into therapies for chronic disease. Join now to hear the strategy firsthand and get your questions answered live.
⚡ Why you should be in the room:
More than 270 patents issued and pending
Fibroblasts are abundant, easy to grow and naturally drawn to tumors and injured tissue
Disc disease spheroids that preserved disc height better than any other fibroblast approach tested
A newly granted European patent for tumor-targeting fibroblast delivery
A pipeline spanning multiple chronic disease indications
Register now and join us live at 4:15 PM ET.
🔗 Register here: redchip.news/4fchsh2
#FBLG #FibroBiologics #CellTherapy #Fibroblasts #RegenerativeMedicine #WoundHealing #Biotech #NasdaqStocks #InvestorWebinar #SmallCapInvesting
162
🚨 TODAY: FibroBiologics (NASDAQ: FBLG) Live Investor Webinar at 4:15 PM ET
The FibroBiologics investor webinar is today. This afternoon, management will present a cell therapy platform built on fibroblasts, with programs across chronic disease, regenerative medicine and cancer. Bring your questions on the pipeline, the patent portfolio and upcoming milestones.
📋 What’s on the table today:
A clinical-stage platform using fibroblasts and fibroblast-derived materials
More than 270 U.S. and international patents issued and pending
Preclinical disc disease data showing an 80.7% disc height index versus 71.8% in controls at 12 weeks
A European patent covering fibroblasts that carry oncolytic viruses into tumors
Programs spanning wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, longevity and cancer
Register now to join the live presentation this afternoon.
🔗 Register here: redchip.news/4fchsh2
#FBLG #FibroBiologics #CellTherapy #Fibroblasts #RegenerativeMedicine #WoundHealing #Biotech #NasdaqStocks #InvestorWebinar #SmallCapInvesting
136
In the first half of 2026, edgeTI (OTCQB: $UNFYF) reported revenue of approximately 3.7 million, up 211% from a year earlier. CEO Jason Nichols says the Australian acquisition from Austal contributed substantially, while U.S. operations grew 38%.
The goal now is to grow revenue while improving efficiency and cash performance. Progress will be measured by pipeline, signed programs, successful delivery and better financial results.
Watch the full interview with edgeTI CEO Jason Nichols at redchip.news/4t7bHXZ, and join the RedChip Nation to discover more companies like edgeTI.
$UNFYF #edgeTI #DefenseTech #SmallCaps #CEOInterview #RedChip
162
A historic milestone for First Phosphate (Nasdaq: $PHOS). UK Export Finance has issued a letter of interest for up to C$220 million in export credit support for the company’s Bégin-Lamarche phosphate mine in Quebec. It joins Denmark and Switzerland, bringing proposed government-backed financing to about US$567.5 million. That exceeds the mine’s estimated US$475 million construction CAPEX, before the feasibility study is even released. On top of that, First Phosphate has C$21.5 million in non-repayable Canadian government contributions and offtake support from Italian export credit and development finance agencies. Lining up this much financing this early is rare for a critical minerals developer, and it puts First Phosphate well ahead in building a North American supply chain for LFP batteries.
Learn more: redchip.news/4C7w5fy
#FirstPhosphate #PHOS #CriticalMinerals #LFP #BatteryStorage #Phosphate #Mining #ExportFinance #SmallCapStocks #RedChip
1
199
Vector Science and Therapeutics (TSXV: $PAIN): Andrews Research & Education Foundation Partners with Vector to Develop Peptides for Sports and Regenerative Medicine
Vector Science and Therapeutics (TSXV: PAIN) announced a collaboration with the Andrews Research & Education Foundation, founded by renowned sports medicine surgeon Dr. James Andrews. Together they will design clinical programs testing Vector’s pharma-grade peptides for soft tissue repair, muscle regeneration in aging athletes and osteoarthritis. Vector will manufacture and supply the peptides, any new intellectual property will be jointly owned, and Vector will lead commercialization through its direct-to-physician sales model. The partners will also build peptide education programs for physicians through the foundation’s sports medicine network. Dr. Andrews and Vector Chairman Tommy Thompson will host a livestreamed briefing today at 11:00 a.m. CST (12:00 p.m. ET).
Full press release: redchip.news/48ZG60X
1
1
168
Foremost Clean Energy (Nasdaq: $FMST): New Uranium Discovery at Turkey Lake Adds a Second Target Area Alongside Hatchet Lake
Foremost Clean Energy (Nasdaq: FMST) discovered uranium in its first-ever drill program at the Turkey Lake project in Saskatchewan’s Athabasca Basin. Hole TL-26-02 returned 0.13% eU₃O₈ over 3.0 metres, including 0.29% over 0.5 metres. What matters most for investors is the location. The discovery sits outside the area historical drilling focused on, which could point to an entirely new mineralized trend on the property. Several similar untested targets remain nearby. Combined with the high-grade discovery at Hatchet Lake, Foremost now has two areas worth follow-up drilling. The next catalyst is chemical assay results, which are pending.
Full press release: redchip.news/4zsxAT2
1
152
Bimergen Energy (NYSE American: $BESS) posted its second straight profitable quarter. Q3 net income rose 50% from Q2 to $2.4 million, on revenue of $3.0 million. The company sold stakes in three Texas battery storage projects while keeping 7.5% of each for long-term upside. With about 2.0 GW across 33 projects still in development, Bimergen sees more opportunities to turn its pipeline into revenue.
Full press release: redchip.news/4C94omD
#Bimergen #BESS #BatteryStorage #EnergyStorage #CleanEnergy #GridReliability #SmallCapStocks #RedChip
148
Greenwich LifeSciences (Nasdaq: $GLSI): Phase III Breast Cancer Immunotherapy Trial to Be Featured at Major Oncology Conference December 9
Greenwich LifeSciences (Nasdaq: GLSI) will present two posters on its Phase III FLAMINGO-01 trial at the San Antonio Breast Cancer Symposium on December 9. The global trial is evaluating GLSI-100, an FDA Fast Track-designated immunotherapy designed to prevent breast cancer recurrence following surgery. Earlier Phase II results showed no recurrences among fully immunized patients, providing the foundation for the Phase III program, which had expanded to more than 170 clinical sites across the U.S. and Europe as of July 2026. The upcoming presentations will put the program before leading oncology researchers at a conference expected to attract approximately 10,000 healthcare professionals. Both posters are authored by the trial's Steering Committee, with additional details expected during the conference.
Full press release: redchip.news/3WMpCqi
2
370
⏰ One Week Away: Nord Precious Metals (OTCQB: $NPMMF, TSXV: NTH) Live Investor Webinar, Tuesday, November 24 at 4:15 PM ET
The Nord webinar is one week away. Most junior miners have to discover, define and develop a deposit before they can generate revenue. Nord already controls silver in historic tailings at surface, along with existing processing infrastructure, giving it a potentially faster and less capital-intensive route to production.
📈 What’s driving the story:
Historic tailings at surface offer a potentially lower-cost, faster path to production than conventional mine development
Nord operates TTL Laboratories, the Cobalt Camp’s only permitted high-grade milling facility
It owns a 600-tonne-per-day modular gravity plant intended for tailings recovery
Future production cash flow could help fund exploration and reduce reliance on equity financing
Upcoming catalysts include permitting, metallurgical studies, project economics and plant commissioning
Secure your seat today to hear management’s view of the road ahead.
🔗 Register here: redchip.news/4fabXQ3
#NPMMF #NTH #NordPreciousMetals #Silver #SilverStocks #Mining #JuniorMining #Ontario #OTCQB #InvestorWebinar
134
📣 Two Days Out: FibroBiologics (NASDAQ: FBLG) Live Investor Webinar, Thursday, November 19 at 4:15 PM ET
If you haven’t registered yet, now is the time. On Thursday, management will discuss FibroBiologics’ fibroblast-based pipeline and recent progress in intellectual property and preclinical research. It’s a direct chance to ask about clinical plans, pipeline priorities and the path forward.
🎯 Topics to hear about:
The company’s clinical-stage pipeline in chronic disease
Its degenerative disc disease program, which uses allogeneic, cartilage-forming cells designed to restore what the disc has lost
Its oncology approach: fibroblasts engineered as tumor-homing delivery vehicles
A patent portfolio of more than 270 issued and pending patents, including the newly granted European patent
Indications spanning wound healing, multiple sclerosis, psoriasis, orthopedics and human longevity
Register now so you can join the live presentation and Q&A.
🔗 Register here: redchip.news/4fchsh2
#FBLG #FibroBiologics #CellTherapy #Fibroblasts #RegenerativeMedicine #WoundHealing #Biotech #NasdaqStocks #InvestorWebinar #SmallCapInvesting
121
More than 100 million people over age 65 get the seasonal flu each year, and many of them need an alternative to the vaccine. Traws Pharma (Nasdaq: TRAW) is developing an oral medication to prevent seasonal flu, which the company says would be the first of its kind and which targets a $5 billion market. The company is led by an experienced drug developer and a former director of the CDC. The key catalyst for investors is Phase 2 clinical data, which is expected in the near term.
Learn more: redchip.com/stocks/TRAW
#TrawsPharma #TRAW #Nasdaq #Biotech #Influenza #FluSeason #FluPrevention #InfectiousDisease #ClinicalTrials #BiotechStocks #SmallCapStocks #MicroCap #RedChip
187
Cancer claims about 10 million lives a year, and an estimated 90% of those deaths come from metastatic cancer. TransCode Therapeutics (Nasdaq: $RNAZ), led by scientists from Harvard Medical School, is developing a treatment for metastatic cancer. In a Phase 1 trial, its lead drug candidate showed favorable safety and tolerability, and the disease stabilized in some patients. It is now in a Phase 2 trial in colorectal cancer, the next key step for the program.
#TransCodeTherapeutics #RNAZ #Nasdaq #Biotech #Oncology #MetastaticCancer #ColorectalCancer #CancerResearch #ClinicalTrials #RNATherapeutics #BiotechStocks #SmallCapStocks #MicroCap #RedChip
Learn more: redchip.com/stocks/RNAZ
206
BioVie (Nasdaq: $BIVI): Phase 2 Long COVID Data Identify Patient Groups That May Benefit Most From Bezisterim
BioVie presented findings from its Phase 2 ADDRESS-LC trial at the 4th Long COVID International Conference in Nice, France. Exploratory analyses identified two biologically distinct patient groups with different responses to bezisterim. Patients with elevated inflammation showed statistically significant improvements in cognition, while those with low white blood cell levels showed promising effects on fatigue and post-exertional malaise. Bezisterim also reduced neuropeptide Y (NPY) levels by approximately 33% versus placebo, a statistically significant finding involving a biomarker added to the NIH's RECOVER prioritization list. BioVie says the results support a more targeted approach to future Long COVID trials. The study was fully funded by a $13.13 million U.S. Department of War award, and bezisterim's safety profile was comparable to placebo.
Full press release: redchip.com/stocks/BIVI
1
186
Venu Holding Corporation (NYSE American: $VENU): Assets Surge 59% to $587.6 Million as Two New Amphitheaters Prepare to Open
Venu Holding (NYSE American: VENU) reported Q3 2026 results as it prepares to bring two major entertainment venues online. Total assets climbed 59% from year-end 2025 to $587.6 million. Regent Bank Amphitheater in Oklahoma is scheduled to open on New Year's Eve, while Sunset Amphitheater McKinney in Texas is expected to be completed in Q1 2027. Cumulative Luxe FireSuite and Aikman Club sales have surpassed $300 million, with McKinney's Luxe FireSuites 95% sold ahead of opening. At Ford Amphitheater, average revenue per show rose nearly 10% to $609,000. VENU also closed a $60 million sale-leaseback to help fund McKinney's completion while retaining ownership of the amphitheater. With more than 110 event holds across its portfolio for 2027, management expects a meaningful increase in ticketing, food and beverage, and sponsorship revenue as the new venues begin operating.
Full press release: redchip.news/4zsO4uy
158
Vector Science and Therapeutics (TSXV: $PAIN): Dr. James Andrews and Former HHS Secretary Tommy Thompson to Unveil Major Peptide-Related Medical Development November 18
Sports medicine pioneer Dr. James Andrews and Vector Chairman Tommy G. Thompson, former U.S. Secretary of Health and Human Services, will host a livestreamed briefing on November 18 at 11:00 a.m. CST (12:00 p.m. ET) to announce what the company describes as a major medical development involving peptides in the United States. Vector is advancing targeted drug delivery technologies and pharmaceutical-grade prescription peptides for sports medicine, regenerative medicine, pain management and wound care. Its portfolio includes advanced transdermal delivery, precision catheter systems and smart wound care technologies, with peptides manufactured under pharmaceutical quality standards.
Learn more: redchip.news/4C3Q2nB
📣 Nord Precious Metals (OTCQB: $NPMMF, TSXV: NTH) Live Investor Webinar: Tuesday, November 24 at 4:15 PM ET
Nord Precious Metals is advancing a district-scale silver portfolio in Ontario’s historic Cobalt-Gowganda camp, one of the world’s highest-grade primary silver regions. Its strategy has two tracks: a potential near-term path to silver production from historic tailings already at surface, and long-term exploration at the high-grade Castle East discovery. Mark your calendar to hear management outline both.
🔍 Why investors are watching:
An updated NI 43-101 indicated resource of 2.814M ounces of silver grading 47.4 g/t at the Gowganda tailings project
A historical inferred resource of 7.56M ounces of silver grading 8,582 g/t at Castle East
Assets with more than 57 million ounces of historical silver production
Engineering and permitting advancing under Ontario’s streamlined Mineral Recovery Permit framework
A 560-metre surface gold trend that adds potential upside beyond silver
Register now to reserve your spot for the live presentation and Q&A.
🔗 Register here: redchip.news/4fabXQ3
#NPMMF #NTH #NordPreciousMetals #Silver #SilverStocks #Mining #JuniorMining #Ontario #OTCQB #InvestorWebinar #RedChip
1
196







